Clinical Trial Update: Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial of Brentuximab Vedotin in CD30-positive non-lymphomatous malignancies has completed and results were posted in 2016. The study included patients w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Anemia with Excess Blasts
• Myelodysplastic Syndrome
• Solid Tumors

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2016-03-04